98480576 - ACHILLES

Information

  • Trademark
  • 98480576
  • Serial Number
    98480576
  • Filing Date
    April 02, 2024
    9 months ago
  • Transaction Date
    November 16, 2024
    2 months ago
  • Status Date
    November 15, 2024
    2 months ago
  • Location Date
    November 15, 2024
    2 months ago
  • Status Code
    641
  • Current Location
    TMEG LAW OFFICE 104
    Employee Name
    YAPP, CINDY
  • Attorney Docket Number
    60895-593482
    Attorney Name
    Rebecca Liebowitz
    Law Office Assigned Location Code
    L40
  • Owners
Mark Drawing Code
4
Mark Identification
ACHILLES
Case File Statements
  • GS0401: Custom manufacture of therapeutic drugs, namely custom manufacture of cell therapies, cancer therapies, neoantigen-specific T cells, TCR-engineered T cells, cancer vaccines and neoantigen vaccines
  • GS0051: Medical and veterinary preparations for therapeutic purposes; preparations for cancer therapy; antibodies; vaccines; personalised cancer vaccines; neoantigen vaccines; preparations for cell therapy; neoantigen-specific T cells; TCR-engineered T cells; preparations for modifying human or animal cells for medical or therapeutic purposes; preparations of blood extracted from humans or animals which have been adapted for medical or therapeutic purposes
  • GS0441: Medical services; veterinary services; services in the extraction of human and animal cells from patients; manipulation of human and animal cells for therapeutic purposes; reinsertion of cells into human and animal patients; providing advice and consultancy in the field of medical and veterinary therapies; providing advice and consultancy in the field of cancer therapies and cancer vaccines
  • GS0421: Scientific and technological services and research and design relating thereto; industrial analysis and research services; medical and veterinary research services including the manipulation of cells within a laboratory or research facility to enable the cells to be used for medical or therapeutic purposes; scientific research in the development of new cancer therapies, including neoantigen-specific T cells and TCR-engineered T cells; scientific research in human and animal cell therapy; scientific research into vaccines, including personalised cancer vaccines and neoantigen vaccines; scientific research into preparations for manipulating and adapting human and animal cells; consultancy relating to all the aforesaid services
Case File Event Statements
  • 4/2/2024 - 9 months ago
    1 - NEW APPLICATION ENTERED Type: NWAP
  • 7/17/2024 - 6 months ago
    2 - TEAS VOLUNTARY AMENDMENT RECEIVED Type: PARI
  • 9/7/2024 - 4 months ago
    3 - NEW APPLICATION OFFICE SUPPLIED DATA ENTERED Type: NWOS
  • 10/15/2024 - 3 months ago
    4 - ASSIGNED TO EXAMINER Type: DOCK
  • 11/15/2024 - 2 months ago
    6 - NON-FINAL ACTION E-MAILED Type: GNRT
  • 11/15/2024 - 2 months ago
    5 - NON-FINAL ACTION WRITTEN Type: CNRT
  • 11/15/2024 - 2 months ago
    7 - NOTIFICATION OF NON-FINAL ACTION E-MAILED Type: GNRN